Alice T. Shaw, MD, PhD
LUNGevity Foundation has announced that Alice T. Shaw, MD, PhD, joined its Scientific Advisory Board, a group of 20 world-renowned scientists and researchers who guide LUNGevity’s research program. The Scientific Advisory Board is integral to the Foundation, overseeing the scientific strategy and ensuring that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving the lives of lung cancer survivors.
LUNGevity is the only lung cancer organization with a programmatic focus on early detection and Career Development Awards. Its researchers are working to find a better way to detect lung cancer and to better diagnose, treat, and prevent its recurrence. The research program is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer.
“We could not be happier that Dr. Shaw has joined our Scientific Advisory Board,” said Andrea Ferris, President and Chairman of LUNGevity Foundation. “She is a brilliant thinker, an innovator, and a compassionate advocate for her patients. In particular, her groundbreaking work that led to the development of crizotinib has extended and improved the lives of many NSCLC patients.”
Dr. Shaw is Director of the Center for Thoracic Cancers and the Paula O’Keeffe Endowed Chair of Thoracic Oncology at Massachusetts General Hospital. She is also Associate Professor of Medicine at Harvard Medical School. In addition to caring for patients with lung cancer, Dr. Shaw performs clinical and translational research focusing on subsets of non–small cell lung cancer (NSCLC) that have unique driver mutations, such as EGFR, ALK, and ROS1. Her translational research focuses on understanding and making clear the mechanisms of resistance to targeted therapies; she is currently developing novel combination treatment strategies. Her research has helped to develop numerous U.S. Food and Drug Administration–approved targeted therapies for patients with oncogene-driven NSCLC, such as crizotinib (Xalkori) for patients with ALK or ROS1 rearrangements. ■